4/13/2010

RXi Pharmaceuticals agreed to collaborate with miRagen Therapeutics, which develops microRNA-based drugs for cardiovascular and muscular disorders, to discover pharmaceutical targets using microRNA technology. The company also will work with Mirna Therapeutics, a Texas company that focuses on early-stage drugs for cancer.

Related Summaries